Advanced search
Publication Cover
Renal Failure Volume 45, 2023 - Issue 1
Submit an article Journal homepage
1,824
Views
0
CrossRef citations to date
0
Altmetric
Article

Thyroid function analysis after roxadustat or erythropoietin treatment in patients with renal anemia: a cohort study

Xiaomeng ZhengDepartment of Pharmacy, The First Affiliated Hospital of Ningbo University, Ningbo, ChinaView further author information
,
Yiyi JinDepartment of Pharmacy, The First Affiliated Hospital of Ningbo University, Ningbo, ChinaView further author information
,
Tao XuDepartment of Pharmacy, The First Affiliated Hospital of Ningbo University, Ningbo, ChinaView further author information
,
Hongbin XuDepartment of Pharmacy, The First Affiliated Hospital of Ningbo University, Ningbo, ChinaCorrespondence[email protected]
View further author information
&
Suyan ZhuDepartment of Pharmacy, The First Affiliated Hospital of Ningbo University, Ningbo, ChinaCorrespondence[email protected]
View further author information
Article: 2199093 | Received 13 Dec 2022, Accepted 29 Mar 2023, Published online: 12 Apr 2023

References

  • Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379(9818):1–7.
  • Drozdz M, Weigert A, Silva F, et al. Achievement of renal anemia KDIGO targets by two different clinical strategies-a european hemodialysis multicenter analysis. BMC Nephrol. 2019;20(1):5.
  • Mikhail A, Brown C, Williams JA, et al. Renal association clinical practice guideline on anaemia of chronic kidney disease. BMC Nephrol. 2017;18(1):345.
  • Gupta N, Wish JB. Hypoxia-Inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD. Am J Kidney Dis. 2017;69(6):815–826.
  • Chen N, Hao C, Liu BC, et al. Roxadustat treatment for anemia in patients undergoing Long-Term dialysis. N Engl J Med. 2019;381(11):1011–1022.
  • Chen N, Hao C, Peng X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med. 2019;381(11):1001–1010.
  • Rhee CM. The interaction between thyroid and kidney disease: an overview of the evidence. Curr Opin Endocrinol Diabetes Obes. 2016;23(5):407–415.
  • Naseem F, Mannan A, Dhrolia MF, et al. Prevalence of subclinical hypothyroid- dism in patients with chronic kidney disease on maintenance hemodialysis. Saudi J Kidney Dis Transpl. 2018;29(4):846–851.
  • Rhee CM, Kim S, Gillen DL, et al. Association of thyroid functional disease with mortality in a national cohort of incident hemodialysis patients. J Clin Endocrinol Metab. 2015;100(4):1386–1395.
  • Xu H, Brusselaers N, Lindholm B, et al. Thyroid function test derangements and mortality in dialysis patients: a systematic review and meta-analysis. Am J Kidney Dis. 2016;68(6):923–932.
  • Rhee CM, Chen Y, You AS, et al. Thyroid status, quality of life, and mental health in patients on hemodialysis. Clin J Am Soc Nephrol. 2017;12(8):1274–1283.
  • Kalantar SS, You AS, Norris KC, et al. The impact of race and ethnicity upon Health-Related quality of life and mortality in dialysis patients. Kidney Med. 2019;1(5):253–262.
  • Tokuyama A, Kadoya H, Obata A, et al. Roxadustat and thyroid-stimulating hormone suppression. Clin Kidney J. 2021;14(5):1472–1474.
  • Ichii M, Mori K, Miyaoka D, et al. Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis. BMC Nephrol. 2021;22(1):104.
  • Yao B, Wei Y, Zhang S, et al. Revealing a Mutant-Induced receptor allosteric mechanism for the thyroid hormone resistance. iScience. 2019;20:489–496.
  • Maxwell PH. A new approach to treating renal anaemia. Nat Rev Nephrol. 2019;15(12):731–732.
  • Mima A. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: advantages and disadvantages. Eur J Pharmacol. 2021;912:174583.
  • Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019;133(1):40–50.
  • Mima A, Horii Y. Treatment of renal anemia in patients with hemodialysis using hypoxia-inducible factor (HIF) stabilizer, roxadustat: a short-term clinical study. In Vivo. 2022;36(4):1785–1789.
  • Pakfetrat M, Dabbaghmanesh MH, Karimi Z, et al. Prevalence of hypothyroid -dism and thyroid nodule in chronic hemodialysis iranian patients. Hemodial Int. 2017;21(1):84–89.
  • Sanai T, Okamura K, Rikitake S, et al. The high prevalence of reversible subclinical hypothyroidism with elevated serum thyroglobulin levels in chronic kidney disease patients. CN. 2017;87(05):237–244.
  • Narasaki Y, Sohn P, Rhee CM. The interplay between thyroid dysfunction and kidney disease. Semin Nephrol. 2021;41(2):133–143.
  • Pan B, Du X, Zhang H, et al. Relationships of chronic kidney disease and thyroid dysfunction in Non-Dialysis patients: a pilot study. Kidney Blood Press Res. 2019;44(2):170–178.
  • Nazzal ZA, Khazneh EN, Rabi RA, et al. Prevalence of hypothyroidism among dialysis patients in palestine: a Cross-Sectional study. Int J Nephrol. 2020;2020:2683123.
  • Jain D, Aggarwal HK, Pavan Kumar YM, et al. Evaluation of thyroid dysfunc-tion in patients with nephrotic syndrome. Med Pharm Rep. 2019;92(2):139–144.
  • Varghese T, Rejish Kumar VJ, Anand G, et al. Dietary GABA enhances hypoxia tolerance of a bottom-dwelling carp, cirrhinus mrigala by modulating HIF-1α, thyroid hormones and metabolic responses. Fish Physiol Biochem. 2020;46(1):199–212.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.